What Is the Surprising New Treatment for Rheumatoid Arthritis? JAK Inhibitors Explained

The surprising new treatment for rheumatoid arthritis is a class of oral pills called JAK inhibitors. Unlike traditional biologics that require injections or infusions, these small-molecule drugs are taken by mouth and work by blocking the internal signaling pathways that drive joint inflammation.

In clinical trials running over five years, more than three-quarters of patients on upadacitinib, one of the leading JAK inhibitors, achieved remission or low disease activity. For people who have tried and failed multiple biologic treatments, that number is significant.

The bigger picture: RA treatment has shifted from managing symptoms to targeting the disease at its source, earlier and more precisely than ever before. JAK inhibitors are the latest step in that direction.

What Exactly Is Rheumatoid Arthritis Doing to Your Joints?

Rheumatoid arthritis is an autoimmune disease. Your immune system misidentifies the synovial lining of your joints as a threat and attacks it. That attack triggers persistent inflammation driven by proteins called cytokines, specifically TNF-α, IL-6, and IL-1.

Left unchecked, that inflammation destroys cartilage and erodes bone. The damage becomes permanent.

RA affects roughly 5 in every 1,000 people. It's not just joint pain. Fatigue, morning stiffness lasting more than an hour, and swelling in multiple joints simultaneously are common early signs.

The hands, wrists, and feet are usually affected first, and the pattern is typically symmetrical: both wrists, both knuckles.

What makes RA different from osteoarthritis is the mechanism. Osteoarthritis is wear and tear. RA is your immune system attacking healthy tissue. That distinction matters because the treatments are completely different.

What Is the New Treatment for Rheumatoid Arthritis in 2026?

JAK inhibitors are the most significant advance in RA treatment in recent years. They work differently from older biologics. Instead of targeting a single cytokine outside the cell, JAK inhibitors block Janus kinase enzymes inside the cell, enzymes that act as relay switches for multiple inflammatory signals at once.

The result is a broader interruption of the inflammatory cascade, delivered in a once-daily pill rather than a self-injection or hospital infusion.

Upadacitinib (brand name Rinvoq) is a selective JAK1 inhibitor with the strongest long-term data. In the SELECT-BEYOND trial, a five-year study of 498 patients who had already failed at least one biologic, 36% achieved full clinical remission at the five-year mark, and 81% achieved remission or low disease activity on the 15 mg dose. These were patients the older treatments hadn't worked for.

Other approved JAK inhibitors include tofacitinib and baricitinib. Each has a slightly different selectivity profile, which affects both efficacy and side effect risk. Your rheumatologist will match the drug to your specific disease pattern and history.

What Is the Most Successful Treatment for Rheumatoid Arthritis Overall?

The most successful approach is early, aggressive treatment with a clear target: remission or low disease activity within six months.

The first-line drug is still methotrexate, typically at 25 mg weekly, often combined with a short course of glucocorticoids to control inflammation while the methotrexate takes effect. This combination achieves remission or low disease activity in 40 to 50% of patients.

For patients who don't respond within three to six months, the next step is a biologic or JAK inhibitor. Biologics target specific cytokines or immune cells:

• TNF-α inhibitors (etanercept, infliximab, adalimumab), the most widely used second-line option
• IL-6 receptor blockers (tocilizumab, sarilumab), particularly useful when systemic inflammation is high
• B-cell depletion (rituximab), effective for patients with certain antibody profiles
• T-cell costimulation blockers (abatacept), a gentler option with a favorable safety profile
• JAK inhibitors, oral, broad-acting, and effective even after biologic failure

The treat-to-target strategy, measuring disease activity regularly and adjusting treatment until the target is reached, has transformed outcomes. When applied consistently, it prevents the joint damage that used to be considered inevitable.

What most articles miss: the timing of that first treatment decision matters more than which drug you start with. Delays of even a few months in early RA can mean the difference between reversible inflammation and permanent joint damage.

What Does Vicks VapoRub Do for Arthritis?

Vicks VapoRub contains menthol, camphor, and eucalyptus oil. Applied to the skin over a painful joint, menthol activates cold-sensitive receptors that temporarily override pain signals, a mechanism called counter-irritation. It doesn't reduce inflammation or slow disease progression.

In my experience reviewing patient-reported remedies, topical menthol products provide short-term comfort for mild joint pain, particularly at night. They aren't a treatment for RA. They don't affect the autoimmune process, cytokine activity, or joint damage.

Using them instead of prescribed DMARDs while the disease progresses is a real risk. Use them for temporary relief if they help. Don't use them as a substitute for medical treatment.

When Will Reset RA Be Available?

Reset RA refers to emerging research into resetting or re-educating the immune system in autoimmune diseases, essentially trying to stop the misdirected immune attack at its root rather than suppressing it continuously. Some early-phase trials are exploring CAR-T cell therapy and other immune reconstitution approaches for autoimmune conditions including RA.

As of 2025 to 2026, these approaches remain experimental. There's no approved "reset" therapy for RA available to the general public. The most promising immune-resetting research is still in early clinical trials, and timelines for regulatory approval are typically five to ten years from that stage.

What I found was that patients searching for "Reset RA" are often looking for a cure rather than ongoing management. That's a reasonable hope. The current reality is that JAK inhibitors and biologics can achieve sustained remission, which functionally means the disease is controlled to the point where it causes no measurable damage, but they require continued use to maintain that effect.

Three Things Most Articles Get Wrong About RA Treatment

1. Waiting to see if symptoms improve on their own is the most damaging decision you can make. Early RA is the window where treatment prevents permanent damage. Joint erosion visible on X-ray can begin within the first year of untreated disease. The treat-to-target approach works precisely because it closes that window fast.

2. Failing one biologic doesn't mean biologics don't work for you. Different biologics target different pathways. A patient who doesn't respond to a TNF inhibitor may respond well to an IL-6 blocker or a JAK inhibitor. The SELECT-BEYOND trial specifically enrolled patients who had failed biologics, and still showed strong results with upadacitinib. Switching isn't giving up. It's standard protocol.

3. Exercise isn't optional. Most RA content treats exercise as a lifestyle add-on. The evidence says otherwise. Structured physical activity reduces systemic inflammation, preserves joint function, and improves fatigue, all of which directly affect disease outcomes.

When I tried reviewing the data on exercise in autoimmune conditions, the effect sizes were consistently larger than most patients expect. A qualified exercise professional who understands chronic disease can build a program that works around flares and protects vulnerable joints rather than stressing them.

How Does Exercise Fit Into RA Management?

Exercise doesn't replace medication. It works alongside it. The combination of disease-modifying treatment and structured physical activity produces better functional outcomes than either alone.

The key is the right kind of exercise, delivered by someone who understands the condition. High-impact activity during a flare causes harm. Low-load resistance training, hydrotherapy, and mobility work during stable periods build the muscle support that protects joints from the mechanical stress that accelerates damage.

For people managing RA under the NDIS, working with an NDIS personal trainer who has experience in chronic inflammatory conditions means the program is built around your specific joint involvement, your current disease activity, and your functional goals. That specificity matters. Generic gym programs aren't designed for autoimmune joint disease.

If you're in Melbourne and looking for structured support that fits within your NDIS plan, NDIS personal training in Melbourne can provide exactly that kind of tailored, condition-aware exercise support.

What Are the Side Effects of JAK Inhibitors?

JAK inhibitors are effective, but they carry real risks that require monitoring. The most important ones:

• Infections, particularly upper respiratory infections and herpes zoster (shingles). Vaccination before starting treatment is recommended.
• Blood clots, higher-dose tofacitinib showed increased risk of deep vein thrombosis and pulmonary embolism in patients over 50 with cardiovascular risk factors. Upadacitinib at standard doses has a more favorable profile, but risk still exists.
• Cardiovascular events, patients with existing heart disease require careful risk assessment before starting JAK inhibitors.
• Lipid changes, cholesterol levels can rise and should be monitored.
• Liver enzyme elevation, routine blood tests catch this early.

The five-year SELECT-BEYOND data tracked treatment-emergent adverse events throughout the trial period. The safety profile was considered acceptable for a population that had already failed other treatments, but these aren't low-risk drugs. Regular monitoring is part of the treatment protocol, not optional.

Frequently Asked Questions

Are JAK inhibitors better than biologics for RA?

For patients who have failed biologics, JAK inhibitors are often more effective. That's exactly what the SELECT-BEYOND trial tested. For biologic-naive patients, the comparison is less clear-cut. Both are valid second-line options after methotrexate. The choice depends on your disease profile, cardiovascular risk, and preference for oral versus injectable medication.

Can RA go into remission permanently?

Sustained remission is achievable, but most patients require ongoing treatment to maintain it. Stopping medication during remission leads to flares in the majority of cases. Some patients with very early, mild disease who achieve deep remission may be able to taper treatment under close supervision, but this is the exception, not the rule.

How quickly do JAK inhibitors work?

Many patients notice improvement within two to four weeks. Meaningful clinical response is typically assessed at three months, with full evaluation at six months.

Is methotrexate still used with JAK inhibitors?

Sometimes. Upadacitinib can be used as monotherapy or in combination with methotrexate. The SELECT-BEYOND trial included patients on background conventional DMARDs. Your rheumatologist will determine the combination based on your response history and tolerability.

Does diet affect rheumatoid arthritis?

Diet doesn't replace medication, but anti-inflammatory eating patterns, high in omega-3 fatty acids, vegetables, and whole grains, low in processed foods and refined sugar, are associated with lower systemic inflammation markers. No specific diet has been shown in controlled trials to induce remission, but dietary quality affects overall inflammatory burden and cardiovascular risk, both of which matter in RA management.

Can exercise make RA worse?

The wrong exercise at the wrong time can aggravate a flare. Structured exercise designed for RA, with appropriate load, timing, and joint protection, consistently improves outcomes. The risk is unguided exercise, not exercise itself.

What You Should Do Now

If you've been diagnosed with RA and aren't yet in remission, push for a medication review. The target is remission or low disease activity within six months of starting treatment. If your current regimen isn't getting you there, a switch to a biologic or JAK inhibitor is the evidence-based next step, not a last resort.

Three specific actions worth taking this week:

1. Book a rheumatology review and ask specifically about your current disease activity score. If you don't know your DAS28 or CDAI score, you can't track whether treatment is working.
2. Ask about JAK inhibitors if you've tried and failed one or more biologics. The five-year data on upadacitinib is strong enough to make this a direct conversation, not a last-resort discussion.
3. Add structured exercise to your plan. Find a trainer with chronic disease experience, someone who can build a program around your joint involvement and disease activity, not despite it. If you're in Melbourne and on the NDIS, NDIS personal training support is available and can be built into your plan.

The disease is manageable. The tools exist. The gap between knowing that and acting on it is where outcomes are decided.

About the author

Armstrong Lazenby

BSc (Human Nutrition) registered nutritionist. Bachelor of Science (Exercise Science major) Master of Sports Medicine.

Connect on LinkedIn →